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Purpose: To evaluate the effect of intravitreal (IVT) bevacizumab in neovascular age-related 
macular degeneration (AMD) on global choroidal hemodynamics, as measured by ocular pulse 
amplitude (OPA).
Methods: This was a two-center prospective study (Sheba Medical Center, Israel, and University 
Hospitals Leuven, Belgium). AMD patients who required IVT bevacizumab (1.25 mg/0.05 mL; 
first or repeated) were examined three times: at days 0 (prior to injection), 7 (±3), and 28 (±7) 
postinjection. At each visit, OPAs of both eyes were measured using the Pascal dynamic contour 
tonometer (DCT). A paired t-test between preoperative and postoperative OPA was conducted. 
Pearson correlation was used to evaluate the influence of various measured parameters on 
DCT–OPA.
Results: A total of 38 neovascular AMD patients were recruited, and 30 patients were included in 
the final analysis (18 females and 12 males; age 78.8 ± 5.82 years [mean ± standard deviation]). 
A good correlation was found throughout the study between the DCT–intraocular pressure (IOP) 
and Goldmann IOP and between DCT–IOP and DCT–OPA. No change in OPA of bevacizumab-
treated eyes was found between the visits (2.24 ± 0.73, 2.2 ± 0.86, and 2.23 ± 0.73 mm Hg at 
visits 1, 2, and 3, respectively; paired t-test: P = 0.77 between visits 1 and 2, P = 0.98 between 
visits 1 and 3). No correlations were found between DCT–OPA and age, heart rate, systemic 
blood pressure, axial length, keratometry readings, and central corneal thickness.
Conclusions: OPA, an indirect measure of global choroidal hemodynamics, remains unchanged 
following IVT off-label bevacizumab. This finding adds to the growing evidence regarding the 
safety profile of bevacizumab in AMD treatment.
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Introduction
There is evidence that retinal pigment epithelium (RPE)-secreted vascular endothelial 
growth factor-A (VEGF-A) is essential to maintain a normal functioning, fenes-
trated choriocapillaris in order to nourish the RPE and outer retina.1,2 In spite of this, 
VEGF blockage, either by US Food and Drug Administration-approved ranibizumab 
  (Lucentis®, [Genentech Inc., San Francisco, CA, USA]) or off-label bevacizumab 
(Avastin® , [Genentech Inc., San Francisco, CA, USA]), is currently the most common 
treatment modality for neovascular age-related macular degeneration (AMD).
Although the pathogenesis of neovascular AMD is under debate, ischemic hypoxia 
may play a significant role in it, as various studies have already demonstrated altered 
choroidal filling in AMD.3–12 An indirect method to assess global choroidal circulation, 
which accounts for 85% of the total ocular circulation, is by measuring the ocular pulse 
amplitude (OPA).13–15 OPA, which mainly originates from choroidal hemodynamic Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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Table 1 inclusion/exclusion criteria
Inclusion criteria
1. Male or female aged 50 years or over 50 years
2.   Between 0 and 12 prior iVT bevacizumab treatments for subfoveal or 
juxtafoveal choroidal neovascularization due to AMD in the treated eye
3. Willing and able to sign an informed consent form
Exclusion criteria
1.   A history or signs and symptoms of any retinal or optic nerve disease, 
except AMD with or without mild hypertensive retinopathy
2.   in the bevacizumab-treated eye, prior other anti-VegF (pegaptanib 
or ranibizumab), photodynamic therapy, and/or iVT triamcinolone 
acetonide, during the last 3 months
3.   Any AMD treatment except AReDs formulation for the fellow eye 
during the last 3 months
4.   history of ocular surgery with the exception of uneventful 
extracapsular cataract extraction with posterior chamber  
intraocular lens
5.   history of ocular laser treatment, with the exception of YAg 
capsulotomy for posterior capsule opacification
6.   Cataract or other media opacity precluding adequate fundus 
visualization of both eyes
Abbreviations:  AMD,  age-related  macular  degeneration;  AReDs,  Age-Related 
eye  Disease  study;  iVT,  intravitreal;  VegF,  vascular  endothelial  growth  factor; 
YAg, yttrium aluminum garnet.
changes during the cardiac cycle, was previously found to be 
lower in neovascular AMD compared with nonneovascular 
AMD, as well as   controls.12 Intravitreal (IVT) ranibizumab 
and bevacizumab have a global effect on the amount of all 
isoforms of active ocular VEGF-A. Therefore, in this sus-
ceptible neovascular AMD population, repeated IVT injec-
tions of these anti-VEGF drugs, in addition to their effect on 
pathologic choroidal neovascularization (CNV), may also 
damage the normal choroidal microvasculature, especially the 
choriocapillaris. Of special interest are two recent prospective 
studies that evaluated the aqueous humor levels of different 
cytokines, including VEGF, in neovascular AMD population 
and controls, at baseline and following repeated ranibizumab16 
and bevacizumab.17 Both studies have found anti-VEGF 
therapy to significantly decrease intraocular VEGF levels. 
Also, the study with the greater patient cohort (28 AMD 
eyes, 28 controls)16 found intraocular VEGF at baseline to be 
significantly higher in neovascular AMD eyes compared with 
control eyes undergoing cataract operation (P = 0.033).
The purpose of this study was to evaluate the effect of 
IVT bevacizumab in neovascular AMD on global choroidal 
hemodynamics, as measured by OPA.
We hypothesized that OPA values would be transiently 
reduced 1 week following IVT bevacizumab with a recovery 
to preinjection values 4 weeks post-treatment. This was based 
on recent IVT pharmacokinetics studies that found bevaci-
zumab terminal half-life to be 4.32 days in a rabbit model18 
and between 6.7 and 10 days in AMD patients.19,20
Methods
A total of 38 patients with active subfoveal/juxtafoveal 
CNV/AMD were recruited for this two-center prospec-
tive study conducted at Goldschleger Eye Institute, Sheba 
Medical Center, Israel, and University Hospitals Leuven, 
Belgium. Written informed consent was obtained from all 
participants. The study adhered to the tenets of the Declara-
tion of   Helsinki and was approved by the Institutional Review 
Board in both the hospitals. Table 1 summarizes the study 
inclusion/  exclusion criteria.
Patients were tested over three study visits: 1) on the day 
of the IVT bevacizumab treatment, prior to the injection; 2) 1 
week (±3 days) postinjection; and 3) 4 weeks (±7 days) postin-
jection. Table 2 summarizes the tests performed in each of the 
study visits. Prepupil dilation intraocular pressure (IOP) was 
initially tested twice (the mean of the two measurements was 
taken for analysis) in both eyes of each study patient with a 
calibrated Goldmann applanation tonometer (GAT). This was 
immediately followed by IOP and OPA measurements with 
the Pascal dynamic contour tonometer (Pascal DCT, Swiss 
Microtechnology AG, Port, Switzerland; slit-lamp-mounted, 
self-calibrating, 1-g appositional force, 100-Hz sampling rate, 
7-mm tip diameter, 1.2-mm pressure sensor diameter) in both 
eyes. Up to three DCT measurements were taken in order to 
have one good-quality measurement (quality level 1 to 2). In 
cases in which none of the three measurements was of qual-
ity level 1 or 2, the data from the better quality measurement 
were taken for analysis. In order to eliminate insufficient test 
quality OPA measurements, those patients whose best-quality 
DCT measurement in at least one visit was no better than 5 
(worst quality) were excluded from the final analysis.
Statistical analysis was performed with SPSS statistical 
software package, version 10 (SPSS Inc, Chicago, IL, USA). 
A paired t-test between preinjection and   postinjection OPAs 
at 1 and 4 weeks was performed to evaluate the effect of 
  bevacizumab on OPA. Similar comparisons were performed 
for the fellow eye, which served as a negative control. 
  Univariate Pearson correlation was used to evaluate the 
influence of various measured parameters (Table 2) on the 
DCT–IOP and DCT–OPA.
Results
One patient could not attend visit 2 and was removed from the 
study analysis. All other 37 patients with neovascular AMD Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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completed the study. In the final analysis, the data of seven 
of these patients were excluded. Six patients were excluded 
due to inadequate DCT quality measurements (best-quality 
measurement with DCT in at least one visit = 5), and one 
patient was excluded due to severe systemic hypertension in 
one of the visits (which may change the OPA value). The final 
analysis was therefore conducted on data from 30 patients, 
15 patients from each center.
The age of the study population was 78.8 ± 5.82 years 
(mean ± standard deviation [SD]; range: 69–92). Of the 
30 study patients, 18 patients were female. A total of 
13 patients had been treated for systemic hypertension, and 
one patient had been treated for type 2 diabetes mellitus 
without retinopathy.
Mean visual acuity at baseline was 0.634 ± 0.409 
  ([logMAR (mean ± SD); Snellen equivalent 20/85]) in the 
  bevacizumab-treated eye and 0.766 ± 0.626 ([logMAR 
(mean ± SD); Snellen equivalent 20/118]) in the fellow 
eye. Table 3 summarizes the ocular characteristics of the 
30   participants. Ninety percent of the bevacizumab-treated eyes 
had subfoveal CNV , and half of the lesions were of the occult 
type. At baseline, the prior number of IVT bevacizumab treat-
ments was 2.17 ± 2.53 (mean ± SD; range: 0–9; 12 treatment 
naive; no eye received prior ranibizumab), and only four of the 
treated eyes received prior photodynamic therapy with vere-
porfin. Table 4 summarizes the bevacizumab-treated eyes’ visual 
acuity, GAT–IOP, DCT–IOP, and DCT–OPA in all visits.
Among all IOP/OPA–DCT measurements in the final 
analysis (best measurement of each eye in each visit), 58.0% 
had a quality score of 1 (best), 21.2% with a quality score of 2, 
19.2% with a quality score of 3, and only 1.6% with a quality 
score of 4. Good correlation was found between the DCT–
IOP and GAT–IOP measurements throughout the study, with 
slightly higher values obtained with the DCT (Table 4 and 
Figure 1). DCT–IOP and DCT–OPA measurements showed 
Gaussian distributions, which eliminated the need to convert 
them into logarithmic units. A positive correlation was found 
between DCT–OPA and DCT–IOP (Figure 2).
This study did not find any significant change in 
  bevacizumab-treated eye DCT–OPA from visits 1 to 2 (paired 
t-test, P = 0.77) and from visits 1 to 3 (paired t-test P = 0.98; 
Table 4). Because OPA is dependent on IOP, the change in 
the DCT–OPA/DCT–IOP ratio was also evaluated in order 
to isolate the pulsatile blood flow component. No change in 
OPA/IOP ratio was found between visits 1 and 2 or between 
visits 1 and 3 (bevacizumab-treated eye, t-test: P = 0.377 for 
visits 1–2; P = 0.679 for visits 1–3).
Table 2 schedule of visits and procedures
Pretreatment Visit 1 Visit 2 Visit 3
Clinic visit/day 
of injection
On the day of IVT 
bevacizumab
A week (±3 days) post-IVT 
bevacizumab
4 weeks (±7 days) post-IVT 
bevacizumab
Recruitment ×
Medical/ocular history ×
hR and BP1 × × ×
VA2 × × ×
iOP with gAT followed  
by iOP and OPA with 
DCT3
× × ×
Biomicroscopic examination,  
FA, and OCT results from  
the clinical notes4
×
As seen on the preinjection visit
× ×
As seen during the clinical 
visit at this day
Axial length, K reading, and  
CCT of both eyes5
×
During any of the three study visits
Notes: 1hR and systemic BP were measured after 5 min of rest, in a sitting position; 2VA test of both eyes, using the patient’s glasses for distance and through a pinhole, on 
a snellen chart; 3iOP with gAT; iOP and OPA with Pascal DCT; 4Biomicroscopic examination at each visit; last FA test prior to study entry; OCT at baseline and at the end 
of the study; 5Axial length and corneal curvature (K reading) measurements using iOL Master (Carl Zeiss Ag, Feldbach, switzerland); CCT measurements with an ultrasonic 
pachymeter (mean of three readings within a range of ±5 μm was taken for analysis).
Abbreviations: BP, blood pressure; CCT, central corneal thickness; DCT, dynamic contour tonometer; FA, fluorescein angiography; GAT, Goldmann applanation tonometer; 
hR, heart rate; iOP, intraocular pressure; iVT, intravitreal; K, keratometry; OCT, optical coherence tomography; OPA, ocular pulse amplitude; VA, visual acuity.
Table 3 Ocular characteristics
Study eye Fellow eye
Axial length (mm; mean ± sD) 23.45 ± 0.87 23.53 ± 1.07
Keratometry reading  
(D; mean ± sD)
43.38 ± 1.62 43.47 ± 1.5
Central corneal thickness  
(μm; mean ± sD)
552.93 ± 36.26 553.43 ± 38.76
Pseudophakia (no. of eyes/total) 14/30 11/30
Abbreviation: sD, standard deviation.Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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No correlations were found between DCT–OPA and age, 
heart rate, systolic/diastolic/mean systemic blood pressure, axial 
length, keratometry readings, and central corneal thickness.
Discussion
Earlier studies using different techniques, such as fluores-
cein angiography, indocyanine green angiography, laser 
Doppler flowmetry, color Doppler imaging, and Langham 
ocular blood flowmetry (Langham OBF), have found altered 
ocular hemodynamics in AMD patients.3–12 Among these 
earlier studies, Mori et al, using the Langham OBF, which 
measures the IOP, OPA, and pulsatile OBF, found neovas-
cular AMD patients to have significantly lower OPA and 
calculated pulsatile OBF as compared with nonneovascular 
AMD, as well as controls.12 Also, a recent study by Boltz 
et al found low subfoveal choroidal perfusion and low fundus 
pulsation amplitude (as assessed by laser Doppler flowmetry 
and laser interferometry, respectively) to be risk factors for 
the development of CNV in the fellow eye of patients with 
unilateral CNV .21
Today, data supporting a causal role for VEGF in ocular neo-
vascularization, including neovascular AMD, are   extensive.22 
A recent AMD/ranibizumab prospective human study, with 
1-year follow-up, has found aqueous humor VEGF levels in 
treatment-naive eyes with recent neovascular AMD to be double 
those of age-matched controls (median 85.57 and 41.54 pg/mL, 
respectively; P = 0.033).16 A month following the first ranibi-
zumab treatment, intraocular VEGF was below the detection 
level in 85% of eyes.16 A redetection in VEGF levels below 
detection was only measured after treatment with a previous 
injection 1 month before.16 Another recent study has evaluated 
the effect of three consecutive IVT 1.25-mg bevacizumab 
injections, every 7 (±2) weeks, on the aqueous humor level 
of different cytokines, including VEGF.17 In that study, the 
mean ± SD aqueous humor level of VEGF was 68.0 ± 32.1 
pg/mL at baseline in the AMD group and 51.2 ± 33.4 pg/mL in 
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Figure 1 The correlation between iOP measurements obtained by gAT and DCT 
(bevacizumab-treated eyes, at baseline). Regression line (central) and 95% confidence 
boundaries (top and bottom lines; Pearson correlation r = 0.85, P , 0.001). DCT–
iOP values were slightly higher than gAT–iOP (iOP difference: 1.35 mm hg; Paired 
t-test: P , 0.001).
Abbreviations: DCT, dynamic contour tonometer; gAT, goldmann applanation 
tonometer; iOP, intraocular pressure.
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Figure 2 The correlation between DCT–iOP and DCT–OPA (bevacizumab-treated 
eyes, at baseline). Regression line (central) and 95% confidence boundaries (top 
and bottom lines). DCT–OPA showed positive correlation to DCT–iOP (Pearson 
correlation: r = 0.44, P = 0.014).
Abbreviations:  DCT,  dynamic  contour  tonometer;  iOP,  intraocular  pressure; 
OPA, ocular pulse amplitude.
Table 4 Bevacizumab-treated eyes’ VA, iOP, and OPA during the study
Visit # logMAR (mean ± SD) 
(Snellen equivalent)
IOP (mean ± SD) OPA (mm Hg; mean ± SD)   
(range)
Visit 1 (baseline) 0.634 ± 0.409
(∼20/85)
14.02 ± 3.09 (gAT)
15.36 ± 2.78 (DCT)
2.24 ± 0.73
(0.8–3.6)
Visit 2 (day 7 ± 3) 0.581 ± 0.335
(∼20/76)
13.95 ± 2.37 (gAT)
14.39 ± 2.25 (DCT)
2.20 ± 0.86
(1–4.5)
Visit 3 (day 28 ± 7) 0.612 ± 0.417
(∼20/82)
13.90 ± 2.55 (gAT)
15.17 ± 2.79 (DCT)
2.23 ± 0.73
(0.7–3.6)
Abbreviations: DCT, dynamic contour tonometer; gAT, goldmann applanation tonometer; iOP, intraocular pressure; OPA, ocular pulse amplitude; sD, standard deviation; 
VA, visual acuity.Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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the control group (P = 0.131). The VEGF level was significantly 
reduced to 26.3 ± 19.0 pg/mL after the first IVT bevacizumab 
injection (P = 0.028) and to 25.2 ± 12.8 pg/mL after the second 
injection compared with the baseline value (P = 0.005).17
In light of recent reports, there is evidence to suggest that 
RPE-secreted VEGF constitutively signals normal choroidal 
endothelial cells in vivo.1,2 It is believed that this paracrine 
communication mediates the maintenance of a normally 
functioning, fenestrated, and quiescent choriocapillaris in 
the adult, which is required to nourish the RPE and outer 
retina, including the photoreceptor cells.1 In tissue culture, 
multiple retinal cell types produce VEGF and increase pro-
duction under hypoxic conditions in the microenvironment.22 
Fenestrated vessels appear to be especially sensitive to VEGF 
withdrawal.23–26 In an animal study using adult mice, VEGF 
inhibition resulted in transient capillary regression in the 
normal choroid plexus, pancreatic islets, thyroid, adrenal 
cortex, pituitary, small intestinal villi, and epididymal adipose 
tissue.25 In another study, conditional inactivation of VEGF 
expression in the RPE in mice eyes resulted in the absence 
of choroid. Instead, underneath the RPE, dense collagenous 
tissue resembling sclera was observed.2
Early penetration studies using full-length anti-VEGF 
antibodies, similar to bevacizumab and the Fab fragment 
ranibizumab, seemed to indicate that the full-length antibody 
penetrates the retina poorly, whereas the Fab fragment pen-
etrated the neurosensory retina well.27 This has led Genentech 
to focus their clinical neovascular AMD studies on ranibi-
zumab alone. However, recent penetration studies refute the 
earlier findings, demonstrating bevacizumab to have a rapid 
and full thickness neurosensory retina penetration.28–30 Peters 
et al have recently reported that IVT 1.25 mg of bevacizumab 
to eyes of monkeys caused ultrastructural changes in the cho-
riocapillaris.31 In their study, a significant reduction of cho-
riocapillaris endothelial cell fenestrations was seen as early 
as 24 hours after injection, and their number increased again 
after 2 weeks. On day 14, after IVT bevacizumab, the effect in 
closing endothelial cell fenestrations was already diminished, 
but there were still significantly fewer fenestrations than those 
in untreated eyes. Furthermore, the Peters et al study provided 
an indication of choriocapillaris perfusion disturbances. 
Although severe photoreceptor damage was rare, they have 
raised this as a potential risk of bevacizumab.
At present, little is known about the effect of bevacizumab 
on the histological morphology of CNV in humans. Recently, 
the histological findings in a single surgically excised 
membrane from a patient with repeated IVT bevacizumab 
treatments who developed an RPE tear have been reported.32 
The authors described a specimen that consisted of a largely 
fibrotic choroid, an irregular Bruch’s membrane, and an 
avascular subretinal RPE proliferation set in a fibrous tissue. 
The most striking observation in the tissue was the lack of 
capillaries both in the choroid and in the CNV elements.
The results of the currently ongoing National Eye Insti-
tute Comparisons of Age-Related Macular Degeneration 
Treatments Trials (CATT),33 with head-to-head comparisons 
regarding the clinical efficacy and safety of ranibizumab and 
bevacizumab, are expected to be published in 2012. However, 
this trial will not address the potential subclinical side effects 
of transiently altered choroidal circulation.
Pascal DCT is a new tonometer designed to measure IOP 
and OPA, and hence it can also provide choroidal hemodynam-
ics global data, mainly on the pulsatile choroidal component. 
As opposed to the Langham OBF, DCT does not, at present, 
calculate the pulsatile OBF value from OPA. On the other 
hand, DCT is more accurate than Langham OBF in measur-
ing the IOP and OPA and was recently shown to have good 
concordance with intracameral IOP.34 Recent studies show 
IOP measurements by DCT to be highly concordant with 
IOP readings obtained from GAT.35–37 Our study findings are 
in agreement with the literature, showing good correlation 
between the DCT–IOP and GAT–IOP measurements through-
out the study, with slightly higher values with the Pascal DCT. 
Also, our study found a positive correlation between DCTs 
OPA and IOP, similar to the reports in literature.38,39 Previous 
studies, however, conducted on younger subjects38–41 have 
found a negative correlation between axial length and OPA. 
Romppainen et al and McBrien and Gentle have suggested that 
this may be due to inherently reduced scleral rigidity in myopic 
eyes, resulting in less resistance to enlargement of the pulsatile 
volume.40,42 Our study did not find such a negative correlation 
between axial length and OPA. This result may be due to the 
lack of patients having high myopia in our study (mean ± SD 
axial length of 23.45 ± 0.87 mm, which represents an overall 
emmetropic population). Another possible explanation for our 
result is that the scleral rigidity in elderly people with AMD 
is higher than that in the younger subjects who participated in 
the previous studies. Support for this comes from Pallikaris 
et al,43 who found a significant positive correlation between the 
rigidity coefficient and age, as well as from Friedman et al,44 
who found an increased scleral rigidity in AMD subjects as 
compared with controls. There are little data available regard-
ing the normal values of DCT–OPA in the aged population. 
In the Grieshaber et al study, where the mean age of the 
29 subjects was 64.0 ± 8.3 years (mean ± SD; range 43–80 
years), OPA   values were 2.3 ± 0.9 mm Hg (mean ± SD).39 Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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In the Stalmans et al study, the mean age of the 22 controls 
was 68.5 ± 8.9 years, and the mean OPA values were around 
3.4 ± 1.6 mm Hg.45 Our study population was much older than 
those in the two aforementioned studies (78.8 ± 5.82 years; 
mean ± SD), and OPA values were 2.24 ± 0.73 mm Hg 
(mean ± SD) at baseline. Because no published study has yet 
evaluated DCT–OPA in the elderly population, it is difficult 
to conclude whether patients with neovascular AMD have 
lower than normal DCT–OPA values, as found with the 
Langham OBF.12
In a review of the literature, no prior study has yet 
evaluated the effect of bevacizumab or any other anti-
VEGF treatment on OPA in AMD or in any other ocular 
disease. In this study, IVT off-label bevacizumab, at a 
1.25 mg/0.05 mL dose, was not found to cause a global 
choroidal hemodynamic deficit, as measured by the DCT–
OPA and DCT–OPA/IOP ratio 1 and 4 weeks following 
treatment. There may be several plausible explanations to 
these findings. It is possible that the amount of bevacizumab 
that reached the choriocapillaris within the first week post-
IVT bevacizumab is not sufficient to cause a significant 
transient choriocapillaris regression to alter the choroidal 
resistivity to blood flow and to affect the OPA. It is also 
possible that some choriocapillaris damage does occur, 
but the larger choroidal vessels are not affected, and hence 
global choroidal circulation, as measured by OPA, does not 
significantly change. In addition, the number of patients in 
this study was relatively small (n = 30), which therefore 
allows us only to conclude that no massive effect of IVT 
bevacizumab on the DCT–OPA and DCT–OPA/IOP ratio 
appears to be present. A more subtle hemodynamic effect 
of bevacizumab might be picked up only in a much larger 
study. Ideally, such a study should recruit only treatment-
naive patients and have a long follow-up.
Because OPA is mainly the result of global choroidal 
pulsation, it may not be the most sensitive way to assess the 
possibility of bevacizumab-related choroidal hypoperfusion 
abnormalities in the macular area. To test the latter possibil-
ity, other techniques, such as semiquantitative indocyanine 
green angiography, may be used.46
The results of this pilot study may add data to the safety 
profile of IVT bevacizumab, which is widely used in ophthal-
mology despite the lack of any phase III clinical trial data. 
Although the VEGF-inhibiting effect of ranibizumab and 
bevacizumab is transient, potential future anti-VEGF slow 
release devices still possess the risk of causing transient or 
even permanent choriocapillaris/RPE/outer retina damage 
through their constant elimination of VEGF, which may be 
lower than the minimum amount needed for maintaining a 
properly functioning choriocapillaris.
This study has several major limitations. Apart from 
its small patient cohort, it recruited patients with a dif-
ferent number of previous bevacizumab injections (only 
12 patients were treatment naive), and it had a relatively 
short follow-up.
Dozens of ranibizumab/bevacizumab IVT injections 
may be given to a single eye over a period of years. This 
may result in cumulative damage. A future study with a long 
follow-up, in which only anti-VEGF-naive patients will be 
recruited, can best assess the possibility of such cumulative 
hemodynamic damage. In this regard, two recent studies eval-
uating the potential electroretinographic effects of repeated 
  ranibizumab/bevacizumab injections have been published. 
Zayit-Soudry et al have evaluated the long-term retinal toxicity 
of nine consecutive ranibizumab and bevacizumab biweekly 
injections in rabbits.47 They found electroretinographic and 
visual-evoked potential responses of the experimental and 
control eyes to be similar in amplitude and pattern throughout 
the follow-up period.47 Also, histopathologic evaluation by 
Zayit-Soudry et al yielded similar results, and no retinal 
damage was observed in the experimental and control 
eyes of all rabbits.47 Pedersen et al conducted a 6-month 
prospective pilot human study on 26 eyes of 26 previously 
treatment-naive patients with neovascular AMD receiving 
IVT injections with 1.25 mg bevacizumab.48 All patients were 
examined with multifocal and full-field electroretinography 
(ERG). In full-field ERG, they found a decrease in cone 
photoreceptor function at 3 months, which was normalized 
at 6 months compared with baseline. Their results do not 
show any conclusive signs of global retinal toxicity after 
6 months.48 Instead, multifocal ERG showed improvement 
in photoreceptor function with no sign of focal toxicity in 
the central retina.48 Other studies have looked at the effect of 
repeated anti-VEGF on IOP. In a retrospective study, Adelman 
et al have found a 3.45% rate (4/116 patients) of sustained 
elevated IOP after multiple IVT injections of bevacizumab 
1.5 mg/0.06 mL and/or ranibizumab 0.5 mg/0.05 mL.49 
None of the four patients had a previous diagnosis or family 
history of glaucoma/ocular hypertension (OHT). Two patients 
developed OHT after recent IVT ranibizumab and two 
patients after recent IVT bevacizumab injection.49 A similar 
retrospective study by Good et al has found an increased 
rate of sustained elevation in IOP in patients receiving IVT 
bevacizumab (9.9%) versus those receiving IVT ranibizumab 
(3.1%) (P = 0.049).50 Of interest is the finding that the median 
number of injections prior to peak IOP for the patients who Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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developed sustained elevated IOP was 5, which was lower than 
the median number of injections for eyes without sustained 
IOP elevation (P = 0.002).50
These repeated anti-VEGF injections’ side effects clearly 
demonstrate the need for choroidal hemodynamic studies 
following multiple anti-VEGF procedures.
Another potential limitation of the study is the lower 
visual acuity of the patients’ fellow eyes, which served as a 
control (mean ± SD of logMAR 0.766 ± 0.626 in the fellow 
eyes as compared with 0.634 ± 0.409 in the study eye). These 
fellow eyes’ low vision was due to advanced nonneovacular/
nonactive neovascular AMD. Ideally, control eyes should 
have normal retinal and choroidal vasculature, but this would 
have required a much larger study cohort with an age- and 
gender-matched non-AMD population.
In summary, this small and relatively short-term pilot 
study in a neovascular AMD population found that OPA, 
an indirect measure of global choroidal hemodynamics, 
remains unchanged following IVT bevacizumab. This favor-
able hemodynamic outcome strengthens the safety profile 
of bevacizumab off-label use in ophthalmology. Further 
studies are needed.
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